OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Bishop on 34-Month Data With Anitocabtagene Autoleucel in R/R Myeloma

December 23rd 2024

Michael R. Bishop, MD, discusses 34-month data from the iMMagine-1 trial of anitocabtagene autoleucel in relapsed/refractory myeloma.

Dr Leslie on the 5-Year Follow-Up of the ZUMA-5 Trial in R/R Indolent NHL

December 23rd 2024

Meta: Lori A Leslie, MD, discusses 5-year follow-up data from the ZUMA-5 trial evaluating axi-cel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr Ip on Comparative Findings Between CAR T-Cell Therapies in LBCL

December 20th 2024

Andrew Ip, MD, discusses comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma.

Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma

December 20th 2024

Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.

Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression

December 20th 2024

Elizabeth Buchbinder, MD, discusses the implications of the FDA's decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer

December 20th 2024

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Dr Watson on the Use of Oncogene Analysis to Determine Clinically Relevant HER2, KRAS and MET Copy-Number Gain in NSCLC

December 20th 2024

Alec Watson, MD, discusses clinically relevant thresholds for HER2, KRAS, and MET gene copy number gain set by oncogene overlap analysis in NSCLC.

Dr Sardesai on Lasofoxifene Plus Abemaciclib in ESR1-Mutant, ER+/HER2– Breast Cancer

December 19th 2024

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER-positive, HER2-negative breast cancer.

Dr Emadi on Initial Responses With Venetoclax Plus PegC in R/R AML

December 19th 2024

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.

Dr Baker on the EMBRACE Trial of the Dxcover Liquid Biopsy in Brain Cancer

December 19th 2024

Matthew J. Baker, PhD, discusses the ongoing investigation of the Dxcover Liquid Biopsy for patients with brain cancer in the EMBRACE study.

Dr Ahluwalia on the SURVIVE Trial of SurVaxM Plus Chemoradiation in Newly-Diagnosed Glioblastoma

December 19th 2024

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses the phase 2b SURVIVE trial of SurVaxM plus chemoradiation in newly-diagnosed glioblastoma.

Dr Mascarenhas on Prior Data Showing the Efficacy of Navtemadlin in R/R Myelofibrosis

December 19th 2024

John Mascarenhas, MD, discusses preclinical and clinical data showing symptom improvement and spleen responses with navtemadlin in myelofibrosis.

Dr D'Angelo on the Significance of Lete-Cel Treatment Across Sarcoma Subtypes

December 17th 2024

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Dr Salani on Managing Mirvetuximab Soravtansine–Associated Ocular Toxicities in Ovarian Cancer

December 17th 2024

Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.

Dr Gerds on Efficacy Data Supporting the Use of Momelotinib in Myelofibrosis With Anemia

December 17th 2024

Aaron Gerds, MD, discusses data from the SIMPLIFY-1 and MOMENTUM trials which support the use of momelotinib in myelofibrosis with anemia.

Dr Stahl on Key Genetic Tests for Menin Inhibitor Use in AML

December 17th 2024

Maximilian Stahl, MD, discusses considerations for genetic testing to determine if patients with acute myeloid leukemia may be candidates for a menin inhibitor.

Dr Vivekanandarajah on Identifying HER2-Mutated NSCLC in the Community Setting

December 17th 2024

Abhirami Vivekanandarajah, MD, shares how she tests and treats patients with HER2-mutated non–small cell lung cancer in the community setting.

Dr Halmos on Novel Targets for Drug Development in SCLC

December 16th 2024

Balazs Halmos, MD, discusses novel targets for drug development in small cell lung cancer.

Dr Halmos on the Challenges of Diagnosing SCLC

December 16th 2024

Balazs Halmos, MD, discusses challenges associated with the diagnosis and treatment of patients with small cell lung cancer.

Dr Issa on the Efficacy and Safety of Revumenib in R/R KMT2A+ Leukemias

December 16th 2024

Ghayas C. Issa, MD, discusses the efficacy of revumenib in relapsed or refractory KMT2A-rearranged leukemias.